VDPHL01
/ Veradermics
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
January 23, 2025
Safety and Efficacy of VDPHL01 in Males and Females with AGA
(clinicaltrials.gov)
- P2 | N=70 | Recruiting | Sponsor: Veradermics, Inc. | N=20 ➔ 70 | Trial completion date: Aug 2025 ➔ Mar 2026 | Trial primary completion date: Aug 2025 ➔ Feb 2026
Enrollment change • Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology
December 09, 2024
Efficacy and Safety of VDPHL01 in Males with AGA
(clinicaltrials.gov)
- P2/3 | N=480 | Recruiting | Sponsor: Veradermics, Inc.
New P2/3 trial • Alopecia • Dermatology • Immunology
July 30, 2024
Safety and Efficacy of VDPHL01 in Males With AGA
(clinicaltrials.gov)
- P2 | N=20 | Recruiting | Sponsor: Veradermics, Inc.
New P2 trial • Alopecia • Dermatology • Immunology
1 to 3
Of
3
Go to page
1